Solid Biosciences Inc.
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Solid Biosciences Inc.
The development and commercialization of cell and gene therapies during a pandemic, with regulators and payers demanding more data on effect duration and safety, has resulted in headwinds. Added to manufacturing and clinical trial recruitment issues, investors’ patience has been strained.
Former Novartis CEO Jimenez co-founded Aditum with former NIBR president Mark Fishman; they raised $133m and are launching Tempero Bio. Also, Atea, Galecto and SQZ went public along with one more health care SPAC, Royalty Pharma upped its Vertex royalty revenues and Mirati’s FOPO raised $926.3m.
Another failed study in Duchenne muscular dystrophy spells the end for edasalonexent and possibly the firm.
Ultragenyx enters a competitive and complicated market, but the combination of its manufacturing platform with Solid’s transgene could provide an advantage.
- Medical Devices
- Drug Delivery
- Gene Therapy, Cell Therapy
- Other Names / Subsidiaries
- Solid GT